Erasca said 44 percent of people with KRAS mutated pancreatic cancer responded to its experimental treatment ERAS-0015 in a small Phase 1 trial, supporting a decision to advance the medicine quickly into a Phase 3 study. Response rates were higher in the two largest mutation subgroups, 63 percent in G12D and 80 percent in G12V, which together cover around two thirds of people with KRAS mutated disease. Side effects were mostly mild and nobody stopped treatment because of them, the company said. The study covered 122 people whose pancreatic cancer had progressed after two or more treatment lines, at daily doses of 16 to 32 milligrams.
The data put early pressure on Revolution Medicines’ Rasonque, already on the market and off to one of the strongest oncology launches on record. In its own testing, Rasonque produced responses in 32 percent of the overall population and in 24 percent and 50 percent of G12D and G12V patients respectively, and it is associated with frequent skin rashes. Cross trial comparisons are unreliable and the drugs have not been tested head to head. RBC Capital Markets analyst Leonid Timashev called ERAS-0015 potentially a formidable competitor; TD Cowen’s Tyler Van Buren countered that the early results do not meaningfully differentiate from Rasonque given its multi year commercial head start.
Revolution also released new data this week from an early stage trial of Rasonque combined with chemotherapy in first line pancreatic cancer, where the combination produced responses in 61 percent of patients and left 8 percent with no evidence of active disease. Alterome Therapeutics, another RAS focused company, reported responses in 31 percent of KRAS mutated colorectal cancer patients for its drug ALTA3263 combined with Erbitux.